Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
958 4 |
Ultima descărcare din IBN: 2020-10-18 18:17 |
SM ISO690:2012 BUTUROV, Serghei, GONCIAR, Veaceslav, BUTOROV, Ivan, CALANCEA, Valentin. O nouă abordare a tratamentului bronhopneumopatiei cronice obstructive în exacerbare
. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2012, nr. 1(33), pp. 187-190. ISSN 1857-0011. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale | ||||||
Numărul 1(33) / 2012 / ISSN 1857-0011 | ||||||
|
||||||
Pag. 187-190 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
În studiu a fost studiată efi cacitatea clinică a preparatului antiinfl amator fenspirid la 58 de pacienţi cu bronhopneumopatie cronică obstructivă în exacerbare. Includerea acestui remediu în tratamentul complex al bronhopneumopatiei cronice obstructive favorizează o regresie timpurie a principalelor simptome clinice ale bolii. Concomitent cu efectul pozitiv asupra simptomatologiei clinice, preparatul asigură o diminuare mai evidentă sau normalizarea indicilor infl amaţiei sistemice şi a nivelului
citokinelor proinfl amatoare. Astfel, la fi nele curei de tratament, concentraţia IL-1β a scăzut de 4,8 ori, IL – 8 de 2,5 ori şi TNF–α – de 4,6 ori, pe când în lotul-martor reducerea acestor indici a fost mai puţin pronunţată. |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-16478</cfResPublId> <cfResPublDate>2012-01-03</cfResPublDate> <cfVol>33</cfVol> <cfIssue>1</cfIssue> <cfStartPage>187</cfStartPage> <cfISSN>1857-0011</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/16478</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>O nouă abordare a tratamentului bronhopneumopatiei cronice obstructive în exacerbare </cfTitle> <cfAbstr cfLangCode='RO' cfTrans='o'>În studiu a fost studiată efi cacitatea clinică a preparatului antiinfl amator fenspirid la 58 de pacienţi cu bronhopneumopatie cronică obstructivă în exacerbare. Includerea acestui remediu în tratamentul complex al bronhopneumopatiei cronice obstructive favorizează o regresie timpurie a principalelor simptome clinice ale bolii. Concomitent cu efectul pozitiv asupra simptomatologiei clinice, preparatul asigură o diminuare mai evidentă sau normalizarea indicilor infl amaţiei sistemice şi a nivelului citokinelor proinfl amatoare. Astfel, la fi nele curei de tratament, concentraţia IL-1β a scăzut de 4,8 ori, IL – 8 de 2,5 ori şi TNF–α – de 4,6 ori, pe când în lotul-martor reducerea acestor indici a fost mai puţin pronunţată.</cfAbstr> <cfAbstr cfLangCode='EN' cfTrans='o'>According the 58 patients with chronic obstructive pulmonary disease exacerbation phase was studied the clinical efficacy of anti-infl ammatory drug Fenspirid. Inclusion of this preparation in the treatment of chronic obstructive pulmonary disease favors an early regression of the main clinical symptoms of the disease. The positive effect on clinical symptoms, most obvious preparation ensures a reduction or normalization of indices of systemic inflammation and cytokines. So, the concentration of IL 1β end of the cure of the treatment, decreased 4.8 times, 2.5 times IL-8 and TNF-α, while the control group who received only basic antiinfl ammatory preparations was a less pronounced reduction of inflammatory cytokines.</cfAbstr> <cfAbstr cfLangCode='RU' cfTrans='o'>У 58 больных хронической обструктивной болезнью легких в фазе обострения изучена клиническая эфективность противовоспалительного препарата фенспирид. Включение в комплексную терапию фенспирида способствует более ранней регресии основных клинических симптомов заболевания. Наряду с поло- жительным влиянием на клиническую симптоматику, препарат обеспечивает более выраженное уменьшение или нормализацию маркеров системного воспаления и показателей цитокинового баланса. Так, к окончанию курса лечения концентрация ИЛ-1β снизилась в 4,8 раза, ИЛ-8 – в 2,5 раза, ФНО-α – в 4,6 раза, в то время как в контрольной группе, получавших только базисное лечение, отмечено менее выраженное снижение концентрации противовасполительных цитокинов.</cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-01-03T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2012-01-03T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-19211</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-01-03T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-29739</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-01-03T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11683</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-01-03T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-10744</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-01-03T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-19211</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-19211-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-01-03T24:00:00</cfStartDate> <cfFamilyNames>Buturov</cfFamilyNames> <cfFirstNames>Serghei</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-29739</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-29739-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-01-03T24:00:00</cfStartDate> <cfFamilyNames>Gonciar</cfFamilyNames> <cfFirstNames>Veaceslav</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11683</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11683-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-01-03T24:00:00</cfStartDate> <cfFamilyNames>Буторов</cfFamilyNames> <cfFirstNames>Иван</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-10744</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10744-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-01-03T24:00:00</cfStartDate> <cfFamilyNames>Каланча</cfFamilyNames> <cfFirstNames>В.</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>